Ignacio
Melero

2024

1. CD137 (4-1BB) and T-Lymphocyte Exhaustion

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

3. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

   Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

4. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

5. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

6. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

7. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines

   Cancer discovery, Vol. 14, Núm. 11, pp. 2021-2024

8. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

   Genes and Immunity, Vol. 25, Núm. 5, pp. 437-439

9. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

10. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

    Journal for immunotherapy of cancer, Vol. 12, Núm. 9

11. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

    OncoImmunology, Vol. 13, Núm. 1

12. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

13. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

14. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

15. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

16. Reply to the Letter to the Editor “Reflections on the statistical methodology in nivolumab and ipilimumab therapy research” by S. Yang

    Annals of Oncology

17. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

18. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

19. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

20. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4